



## Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

February 23, 2022

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- [Verve Therapeutics](#), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Cowen 42<sup>nd</sup> Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m. ET.

A live webcast will be available in the investor section of the company's website at [www.vervetx.com](http://www.vervetx.com). The webcast will be archived for 60 days following the presentation.

### **About Verve Therapeutics**

Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve's lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit [www.VerveTx.com](http://www.VerveTx.com).

### **Investor Contact**

Jen Robinson  
Verve Therapeutics, Inc.  
[jrobinson@vervetx.com](mailto:jrobinson@vervetx.com)

### **Media Contact**

Gina Nugent  
Ten Bridge Communications  
[gina@tenbridgecommunications.com](mailto:gina@tenbridgecommunications.com)